{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:31:13Z","timestamp":1791804673476,"version":"4.3.4"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s12016-019-08759-4","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T10:47:57Z","timestamp":1564742877000},"page":"304-322","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Systemic Amyloidosis: a Contemporary Overview"],"prefix":"10.1007","volume":"59","author":[{"given":"Vittorio","family":"D\u2019Aguanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-0421","authenticated-orcid":false,"given":"Massimo","family":"Ralli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Artico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Yoshie","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Scarpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Fiore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Tirassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Severini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"de Vincentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"issue":"6","key":"8759_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583\u2013596. https:\/\/doi.org\/10.1056\/NEJMra023144","journal-title":"N Engl J Med"},{"issue":"2","key":"8759_CR2","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coph.2005.10.005","volume":"6","author":"HJ Lachmann","year":"2006","unstructured":"Lachmann HJ, Hawkins PN (2006) Systemic amyloidosis. Curr Opin Pharmacol 6(2):214\u2013220. https:\/\/doi.org\/10.1016\/j.coph.2005.10.005","journal-title":"Curr Opin Pharmacol"},{"issue":"10038","key":"8759_CR3","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387(10038):2641\u20132654. https:\/\/doi.org\/10.1016\/S0140-6736(15)01274-X","journal-title":"Lancet"},{"issue":"7","key":"8759_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11912-017-0607-4","volume":"19","author":"M Tuzovic","year":"2017","unstructured":"Tuzovic M, Yang EH, Baas AS, Depasquale EC, Deng MC, Cruz D, Vorobiof G (2017) Cardiac amyloidosis: diagnosis and treatment strategies. Curr Oncol Rep 19(7):46. https:\/\/doi.org\/10.1007\/s11912-017-0607-4","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"8759_CR5","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4065\/74.5.490","volume":"74","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A (1999) Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc 74(5):490\u2013494. https:\/\/doi.org\/10.4065\/74.5.490","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"8759_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/hrt.78.1.74","volume":"78","author":"SW Dubrey","year":"1997","unstructured":"Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78(1):74\u201382","journal-title":"Heart"},{"key":"8759_CR7","unstructured":"Wechalekar AD GJ, Foard D, et al. (2012) 25 years of systemic amyloidosis. In: Hazenberg PB (ed) International amyloidosis symposium. Groningen Netherlands,"},{"issue":"3","key":"8759_CR8","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40(3):232\u2013239. https:\/\/doi.org\/10.1080\/07853890701842988","journal-title":"Ann Med"},{"issue":"23","key":"8759_CR9","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1056\/NEJM200206063462312","volume":"346","author":"MJ Saraiva","year":"2002","unstructured":"Saraiva MJ (2002) Sporadic cases of hereditary systemic amyloidosis. N Engl J Med 346(23):1818\u20131819. https:\/\/doi.org\/10.1056\/NEJM200206063462312","journal-title":"N Engl J Med"},{"issue":"7143","key":"8759_CR10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nature05695","volume":"447","author":"MR Sawaya","year":"2007","unstructured":"Sawaya MR, Sambashivan S, Nelson R, Ivanova MI, Sievers SA, Apostol MI, Thompson MJ, Balbirnie M, Wiltzius JJ, McFarlane HT, Madsen AO, Riekel C, Eisenberg D (2007) Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature 447(7143):453\u2013457. https:\/\/doi.org\/10.1038\/nature05695","journal-title":"Nature"},{"issue":"4","key":"8759_CR11","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3181\/00379727-131-34110","volume":"131","author":"L Bonar","year":"1969","unstructured":"Bonar L, Cohen AS, Skinner MM (1969) Characterization of the amyloid fibril as a cross-beta protein. Proc Soc Exp Biol Med 131(4):1373\u20131375. https:\/\/doi.org\/10.3181\/00379727-131-34110","journal-title":"Proc Soc Exp Biol Med"},{"key":"8759_CR12","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1146\/annurev.me.25.020174.001023","volume":"25","author":"GG Glenner","year":"1974","unstructured":"Glenner GG, Terry WD (1974) Characterization of amyloid. Annu Rev Med 25:131\u2013135. https:\/\/doi.org\/10.1146\/annurev.me.25.020174.001023","journal-title":"Annu Rev Med"},{"issue":"12","key":"8759_CR13","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.1073\/pnas.91.12.5602","volume":"91","author":"MB Pepys","year":"1994","unstructured":"Pepys MB, Rademacher TW, Amatayakul-Chantler S, Williams P, Noble GE, Hutchinson WL, Hawkins PN, Nelson SR, Gallimore JR, Herbert J et al (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci U S A 91(12):5602\u20135606","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"8759_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1994.tb00001.x","volume":"25","author":"SY Tan","year":"1994","unstructured":"Tan SY, Pepys MB (1994) Amyloidosis. Histopathology 25(5):403\u2013414","journal-title":"Histopathology"},{"issue":"6","key":"8759_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","volume":"24","author":"JJ Maleszewski","year":"2015","unstructured":"Maleszewski JJ (2015) Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol 24(6):343\u2013350. https:\/\/doi.org\/10.1016\/j.carpath.2015.07.008","journal-title":"Cardiovasc Pathol"},{"issue":"2\u20133","key":"8759_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0014-5793(01)02480-2","volume":"498","author":"MJ Saraiva","year":"2001","unstructured":"Saraiva MJ (2001) Transthyretin amyloidosis: a tale of weak interactions. FEBS Lett 498(2\u20133):201\u2013203","journal-title":"FEBS Lett"},{"issue":"3","key":"8759_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1110\/ps.29002","volume":"11","author":"G Verdone","year":"2002","unstructured":"Verdone G, Corazza A, Viglino P, Pettirossi F, Giorgetti S, Mangione P, Andreola A, Stoppini M, Bellotti V, Esposito G (2002) The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci 11(3):487\u2013499. https:\/\/doi.org\/10.1110\/ps.29002","journal-title":"Protein Sci"},{"key":"8759_CR18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","volume":"51","author":"JN Buxbaum","year":"2000","unstructured":"Buxbaum JN, Tagoe CE (2000) The genetics of the amyloidoses. Annu Rev Med 51:543\u2013569. https:\/\/doi.org\/10.1146\/annurev.med.51.1.543","journal-title":"Annu Rev Med"},{"issue":"5580","key":"8759_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297(5580):353\u2013356. https:\/\/doi.org\/10.1126\/science.1072994","journal-title":"Science"},{"key":"8759_CR20","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1146\/annurev.biochem.75.101304.123901","volume":"75","author":"F Chiti","year":"2006","unstructured":"Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75:333\u2013366. https:\/\/doi.org\/10.1146\/annurev.biochem.75.101304.123901","journal-title":"Annu Rev Biochem"},{"issue":"2\u20133","key":"8759_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1006\/jsbi.2000.4289","volume":"130","author":"J McLaurin","year":"2000","unstructured":"McLaurin J, Yang D, Yip CM, Fraser PE (2000) Review: modulating factors in amyloid-beta fibril formation. J Struct Biol 130(2\u20133):259\u2013270. https:\/\/doi.org\/10.1006\/jsbi.2000.4289","journal-title":"J Struct Biol"},{"issue":"2","key":"8759_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjh.13805","volume":"172","author":"E Kastritis","year":"2016","unstructured":"Kastritis E, Dimopoulos MA (2016) Recent advances in the management of AL amyloidosis. Br J Haematol 172(2):170\u2013186. https:\/\/doi.org\/10.1111\/bjh.13805","journal-title":"Br J Haematol"},{"issue":"3","key":"8759_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/PL00000706","volume":"57","author":"FJ Stevens","year":"2000","unstructured":"Stevens FJ, Kisilevsky R (2000) Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell Mol Life Sci 57(3):441\u2013449. https:\/\/doi.org\/10.1007\/PL00000706","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"8759_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/76216","volume":"6","author":"SD Yan","year":"2000","unstructured":"Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M (2000) Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6(6):643\u2013651. https:\/\/doi.org\/10.1038\/76216","journal-title":"Nat Med"},{"issue":"4","key":"8759_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/1099-1352(200007\/08)13:4<198::AID-JMR499>3.0.CO;2-D","volume":"13","author":"DL Harris","year":"2000","unstructured":"Harris DL, King E, Ramsland PA, Edmundson AB (2000) Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. J Mol Recognit 13(4):198\u2013212. https:\/\/doi.org\/10.1002\/1099-1352(200007\/08)13:4<198::AID-JMR499>3.0.CO;2-D","journal-title":"J Mol Recognit"},{"issue":"3","key":"8759_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1182\/blood.V98.3.714","volume":"98","author":"RL Comenzo","year":"2001","unstructured":"Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA (2001) The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98(3):714\u2013720","journal-title":"Blood"},{"issue":"3","key":"8759_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/13506120009146835","volume":"7","author":"FJ Stevens","year":"2000","unstructured":"Stevens FJ (2000) Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 7(3):200\u2013211","journal-title":"Amyloid"},{"issue":"5","key":"8759_CR28","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.jmb.2006.10.101","volume":"365","author":"AL Gharibyan","year":"2007","unstructured":"Gharibyan AL, Zamotin V, Yanamandra K, Moskaleva OS, Margulis BA, Kostanyan IA, Morozova-Roche LA (2007) Lysozyme amyloid oligomers and fibrils induce cellular death via different apoptotic\/necrotic pathways. J Mol Biol 365(5):1337\u20131349. https:\/\/doi.org\/10.1016\/j.jmb.2006.10.101","journal-title":"J Mol Biol"},{"issue":"2 Suppl 1","key":"8759_CR29","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1212\/01.wnl.0000192103.24796.42","volume":"66","author":"CG Glabe","year":"2006","unstructured":"Glabe CG, Kayed R (2006) Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis. Neurology 66(2 Suppl 1):S74\u2013S78. https:\/\/doi.org\/10.1212\/01.wnl.0000192103.24796.42","journal-title":"Neurology"},{"issue":"20","key":"8759_CR30","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1111\/j.1742-4658.2011.08228.x","volume":"278","author":"TL Williams","year":"2011","unstructured":"Williams TL, Serpell LC (2011) Membrane and surface interactions of Alzheimer\u2019s Abeta peptide--insights into the mechanism of cytotoxicity. FEBS J 278(20):3905\u20133917. https:\/\/doi.org\/10.1111\/j.1742-4658.2011.08228.x","journal-title":"FEBS J"},{"issue":"5","key":"8759_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.bpj.2012.01.039","volume":"102","author":"CC Lee","year":"2012","unstructured":"Lee CC, Sun Y, Huang HW (2012) How type II diabetes-related islet amyloid polypeptide damages lipid bilayers. Biophys J 102(5):1059\u20131068. https:\/\/doi.org\/10.1016\/j.bpj.2012.01.039","journal-title":"Biophys J"},{"key":"8759_CR32","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.med.57.121304.131243","volume":"57","author":"MB Pepys","year":"2006","unstructured":"Pepys MB (2006) Amyloidosis. Annu Rev Med 57:223\u2013241. https:\/\/doi.org\/10.1146\/annurev.med.57.121304.131243","journal-title":"Annu Rev Med"},{"issue":"7","key":"8759_CR33","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1523\/JNEUROSCI.23-07-02665.2003","volume":"23","author":"ME Bamberger","year":"2003","unstructured":"Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE (2003) A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci 23(7):2665\u20132674","journal-title":"J Neurosci"},{"issue":"12","key":"8759_CR34","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1471-4914(01)02173-6","volume":"7","author":"DA Butterfield","year":"2001","unstructured":"Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer\u2019s disease brain: central role for amyloid beta-peptide. Trends Mol Med 7(12):548\u2013554","journal-title":"Trends Mol Med"},{"issue":"11","key":"8759_CR35","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95(11):6448\u20136453","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"8759_CR36","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1523\/JNEUROSCI.19-20-08876.1999","volume":"19","author":"DM Hartley","year":"1999","unstructured":"Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19(20):8876\u20138884","journal-title":"J Neurosci"},{"issue":"6","key":"8759_CR37","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0002-9440(10)63050-7","volume":"159","author":"MM Sousa","year":"2001","unstructured":"Sousa MM, Cardoso I, Fernandes R, Guimaraes A, Saraiva MJ (2001) Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. Am J Pathol 159(6):1993\u20132000","journal-title":"Am J Pathol"},{"issue":"6880","key":"8759_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/416535a","volume":"416","author":"DM Walsh","year":"2002","unstructured":"Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535\u2013539. https:\/\/doi.org\/10.1038\/416535a","journal-title":"Nature"},{"issue":"5","key":"8759_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/0197-4580(96)00115-7","volume":"17","author":"J Rogers","year":"1996","unstructured":"Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P (1996) Inflammation and Alzheimer\u2019s disease pathogenesis. Neurobiol Aging 17(5):681\u2013686","journal-title":"Neurobiol Aging"},{"issue":"5","key":"8759_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/j.1365-2141.2008.07522.x","volume":"144","author":"B Kaplan","year":"2009","unstructured":"Kaplan B, Ramirez-Alvarado M, Sikkink L, Golderman S, Dispenzieri A, Livneh A, Gallo G (2009) Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 144(5):705\u2013715. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07522.x","journal-title":"Br J Haematol"},{"issue":"12","key":"8759_CR41","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1073\/pnas.91.12.5446","volume":"91","author":"MR Hurle","year":"1994","unstructured":"Hurle MR, Helms LR, Li L, Chan W, Wetzel R (1994) A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A 91(12):5446\u20135450","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"8759_CR42","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","volume":"119","author":"V Perfetti","year":"2012","unstructured":"Perfetti V, Palladini G, Casarini S, Navazza V, Rognoni P, Obici L, Invernizzi R, Perlini S, Klersy C, Merlini G (2012) The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood 119(1):144\u2013150. https:\/\/doi.org\/10.1182\/blood-2011-05-355784","journal-title":"Blood"},{"issue":"2","key":"8759_CR43","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1006\/clin.1994.1070","volume":"71","author":"S Ozaki","year":"1994","unstructured":"Ozaki S, Abe M, Wolfenbarger D, Weiss DT, Solomon A (1994) Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstrom\u2019s macroglobulinemia. Clin Immunol Immunopathol 71(2):183\u2013189","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"8759_CR44","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2002-01-0114","volume":"100","author":"V Perfetti","year":"2002","unstructured":"Perfetti V, Casarini S, Palladini G, Vignarelli MC, Klersy C, Diegoli M, Ascari E, Merlini G (2002) Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood 100(3):948\u2013953. https:\/\/doi.org\/10.1182\/blood-2002-01-0114","journal-title":"Blood"},{"issue":"16","key":"8759_CR45","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1016\/j.febslet.2009.04.026","volume":"583","author":"GT Westermark","year":"2009","unstructured":"Westermark GT, Westermark P (2009) Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 583(16):2685\u20132690. https:\/\/doi.org\/10.1016\/j.febslet.2009.04.026","journal-title":"FEBS Lett"},{"issue":"6","key":"8759_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1136\/ard.42.6.665","volume":"42","author":"RE Chambers","year":"1983","unstructured":"Chambers RE, MacFarlane DG, Whicher JT, Dieppe PA (1983) Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 42(6):665\u2013667","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"8759_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00917905","volume":"15","author":"K Zahedi","year":"1991","unstructured":"Zahedi K, Gonnerman WA, Debeer FC, Debeer MC, Steel DM, Sipe JD, Whitehead AS (1991) Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains. Inflammation 15(1):1\u201314","journal-title":"Inflammation"},{"issue":"23","key":"8759_CR48","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1056\/NEJMoa070265","volume":"356","author":"HJ Lachmann","year":"2007","unstructured":"Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361\u20132371. https:\/\/doi.org\/10.1056\/NEJMoa070265","journal-title":"N Engl J Med"},{"issue":"12","key":"8759_CR49","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1517\/14656566.9.12.2117","volume":"9","author":"T Pettersson","year":"2008","unstructured":"Pettersson T, Konttinen YT, Maury CP (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9(12):2117\u20132128. https:\/\/doi.org\/10.1517\/14656566.9.12.2117","journal-title":"Expert Opin Pharmacother"},{"issue":"2\u20133","key":"8759_CR50","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12016-009-8163-9","volume":"38","author":"A Bhat","year":"2010","unstructured":"Bhat A, Selmi C, Naguwa SM, Cheema GS, Gershwin ME (2010) Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 38(2\u20133):97\u2013106. https:\/\/doi.org\/10.1007\/s12016-009-8163-9","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"8759_CR51","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaut.2007.02.017","volume":"28","author":"M Tutaj","year":"2007","unstructured":"Tutaj M, Szczepanik M (2007) Epicutaneous (EC) immunization with myelin basic protein (MBP) induces TCRalphabeta+ CD4+ CD8+ double positive suppressor cells that protect from experimental autoimmune encephalomyelitis (EAE). J Autoimmun 28(4):208\u2013215. https:\/\/doi.org\/10.1016\/j.jaut.2007.02.017","journal-title":"J Autoimmun"},{"issue":"41","key":"8759_CR52","doi-asserted-by":"publisher","first-page":"13527","DOI":"10.1021\/bi00041a032","volume":"34","author":"SL McCutchen","year":"1995","unstructured":"McCutchen SL, Lai Z, Miroy GJ, Kelly JW, Colon W (1995) Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34(41):13527\u201313536","journal-title":"Biochemistry"},{"issue":"6619","key":"8759_CR53","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/385787a0","volume":"385","author":"DR Booth","year":"1997","unstructured":"Booth DR, Sunde M, Bellotti V, Robinson CV, Hutchinson WL, Fraser PE, Hawkins PN, Dobson CM, Radford SE, Blake CC, Pepys MB (1997) Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385(6619):787\u2013793. https:\/\/doi.org\/10.1038\/385787a0","journal-title":"Nature"},{"issue":"19","key":"8759_CR54","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1182\/blood-2012-03-413112","volume":"119","author":"G Merlini","year":"2012","unstructured":"Merlini G (2012) CyBorD: stellar response rates in AL amyloidosis. Blood 119(19):4343\u20134345. https:\/\/doi.org\/10.1182\/blood-2012-03-413112","journal-title":"Blood"},{"issue":"2","key":"8759_CR55","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000098","volume":"2","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ (2013) Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc 2(2):e000098. https:\/\/doi.org\/10.1161\/JAHA.113.000098","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"8759_CR56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2796.2011.02470.x","volume":"272","author":"PT Sattianayagam","year":"2012","unstructured":"Sattianayagam PT, Gibbs SD, Rowczenio D, Pinney JH, Wechalekar AD, Gilbertson JA, Hawkins PN, Lachmann HJ, Gillmore JD (2012) Hereditary lysozyme amyloidosis -- phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 272(1):36\u201344. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02470.x","journal-title":"J Intern Med"},{"issue":"2","key":"8759_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/j.1750-3639.1996.tb00798.x","volume":"6","author":"MM Reilly","year":"1996","unstructured":"Reilly MM, Staunton H (1996) Peripheral nerve amyloidosis. Brain Pathol 6(2):163\u2013177","journal-title":"Brain Pathol"},{"issue":"7","key":"8759_CR58","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","volume":"274","author":"X Hou","year":"2007","unstructured":"Hou X, Aguilar MI, Small DH (2007) Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J 274(7):1637\u20131650. https:\/\/doi.org\/10.1111\/j.1742-4658.2007.05712.x","journal-title":"FEBS J"},{"issue":"4","key":"8759_CR59","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/13506129809007303","volume":"5","author":"Y Ando","year":"1998","unstructured":"Ando Y, Suhr OB (1998) Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid 5(4):288\u2013300","journal-title":"Amyloid"},{"issue":"3","key":"8759_CR60","first-page":"443","volume":"16","author":"PN Hawkins","year":"2003","unstructured":"Hawkins PN (2003) Hereditary systemic amyloidosis with renal involvement. J Nephrol 16(3):443\u2013448","journal-title":"J Nephrol"},{"issue":"6420","key":"8759_CR61","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/362553a0","volume":"362","author":"MB Pepys","year":"1993","unstructured":"Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ et al (1993) Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature 362(6420):553\u2013557. https:\/\/doi.org\/10.1038\/362553a0","journal-title":"Nature"},{"issue":"3","key":"8759_CR62","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1046\/j.1523-1755.2002.00205.x","volume":"61","author":"S Valleix","year":"2002","unstructured":"Valleix S, Drunat S, Philit JB, Adoue D, Piette JC, Droz D, MacGregor B, Canet D, Delpech M, Grateau G (2002) Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family. Kidney Int 61(3):907\u2013912. https:\/\/doi.org\/10.1046\/j.1523-1755.2002.00205.x","journal-title":"Kidney Int"},{"issue":"13","key":"8759_CR63","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH (2005) Diagnosis and management of the cardiac amyloidoses. Circulation 112(13):2047\u20132060. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.104.489187","journal-title":"Circulation"},{"issue":"9","key":"8759_CR64","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1073\/pnas.0912263107","volume":"107","author":"J Shi","year":"2010","unstructured":"Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE, Seldin DC, Falk R, Liao R (2010) Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 107(9):4188\u20134193. https:\/\/doi.org\/10.1073\/pnas.0912263107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"8759_CR65","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.humpath.2011.03.004","volume":"42","author":"Y Sekijima","year":"2011","unstructured":"Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, Hoshii Y, Kato H, Ikeda S (2011) High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol 42(11):1785\u20131791. https:\/\/doi.org\/10.1016\/j.humpath.2011.03.004","journal-title":"Hum Pathol"},{"issue":"18","key":"8759_CR66","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22(18):3751\u20133757. https:\/\/doi.org\/10.1200\/JCO.2004.03.029","journal-title":"J Clin Oncol"},{"issue":"1","key":"8759_CR67","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imj.12288","volume":"44","author":"P Mollee","year":"2014","unstructured":"Mollee P, Renaut P, Gottlieb D, Goodman H (2014) How to diagnose amyloidosis. Intern Med J 44(1):7\u201317. https:\/\/doi.org\/10.1111\/imj.12288","journal-title":"Intern Med J"},{"issue":"Suppl 1","key":"8759_CR68","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/13506129.2011.574354029","volume":"18","author":"A Foli","year":"2011","unstructured":"Foli A, Palladini G, Caporali R, Verga L, Morbini P, Obici L, Russo P, Sarais G, Donadei S, Montecucco C, Merlini G (2011) The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 18(Suppl 1):80\u201382. https:\/\/doi.org\/10.3109\/13506129.2011.574354029","journal-title":"Amyloid"},{"issue":"22","key":"8759_CR69","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","volume":"120","author":"N Leung","year":"2012","unstructured":"Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, Dispenzieri A, Song KW, Kyle RA, International K, Monoclonal Gammopathy Research G (2012) Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 120(22):4292\u20134295. https:\/\/doi.org\/10.1182\/blood-2012-07-445304","journal-title":"Blood"},{"issue":"4669","key":"8759_CR70","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/1831202a0","volume":"183","author":"AS Cohen","year":"1959","unstructured":"Cohen AS, Calkins E (1959) Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183(4669):1202\u20131203","journal-title":"Nature"},{"issue":"4","key":"8759_CR71","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1043\/1543-2165-134.4.512","volume":"134","author":"GA Herrera","year":"2010","unstructured":"Herrera GA, Turbat-Herrera EA (2010) Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med 134(4):512\u2013531. https:\/\/doi.org\/10.1043\/1543-2165-134.4.512","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"8759_CR72","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3109\/13506129709003838","volume":"4","author":"MB Pepys","year":"1997","unstructured":"Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins IM, Hohenester E (1997) Amyloid P component. A critical review. Amyloid 4(4):274\u2013295","journal-title":"Amyloid"},{"issue":"2","key":"8759_CR73","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1182\/blood-2011-06-358507","volume":"119","author":"SO Schonland","year":"2012","unstructured":"Schonland SO, Hegenbart U, Bochtler T, Mangatter A, Hansberg M, Ho AD, Lohse P, Rocken C (2012) Immunohistochemistry in the classification of systemic forms of amyloidosis: a systematic investigation of 117 patients. Blood 119(2):488\u2013493. https:\/\/doi.org\/10.1182\/blood-2011-06-358507","journal-title":"Blood"},{"issue":"7","key":"8759_CR74","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJM199702133360703","volume":"336","author":"DR Jacobson","year":"1997","unstructured":"Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS, Buxbaum JN (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 336(7):466\u2013473. https:\/\/doi.org\/10.1056\/NEJM199702133360703","journal-title":"N Engl J Med"},{"issue":"8","key":"8759_CR75","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1182\/blood-2011-07-365510","volume":"119","author":"F Brambilla","year":"2012","unstructured":"Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, Verga L, Mauri P, Merlini G (2012) Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 119(8):1844\u20131847. https:\/\/doi.org\/10.1182\/blood-2011-07-365510","journal-title":"Blood"},{"issue":"2","key":"8759_CR76","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/bjh.13156","volume":"168","author":"JD Gillmore","year":"2015","unstructured":"Gillmore JD, Wechalekar A, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G, Committee B (2015) Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol 168(2):207\u2013218. https:\/\/doi.org\/10.1111\/bjh.13156","journal-title":"Br J Haematol"},{"issue":"4","key":"8759_CR77","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol 79(4):319\u2013328. https:\/\/doi.org\/10.1002\/ajh.20381","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"8759_CR78","first-page":"48","volume":"17","author":"MAM Gertz","year":"2010","unstructured":"Gertz MAM, G. (2010) Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion. Amyloid: J Protein Folding Disord 17(Suppl. 1):48\u201349","journal-title":"Amyloid: J Protein Folding Disord"},{"issue":"19","key":"8759_CR79","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","volume":"107","author":"G Palladini","year":"2003","unstructured":"Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, Obici L, Ascari E, d'Eril GM, Moratti R, Merlini G (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107(19):2440\u20132445. https:\/\/doi.org\/10.1161\/01.CIR.0000068314.02595.B2","journal-title":"Circulation"},{"issue":"2","key":"8759_CR80","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","volume":"111","author":"AM Maceira","year":"2005","unstructured":"Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111(2):186\u2013193. https:\/\/doi.org\/10.1161\/01.CIR.0000152819.97857.9D","journal-title":"Circulation"},{"issue":"8","key":"8759_CR81","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJM199008233230803","volume":"323","author":"PN Hawkins","year":"1990","unstructured":"Hawkins PN, Lavender JP, Pepys MB (1990) Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med 323(8):508\u2013513. https:\/\/doi.org\/10.1056\/NEJM199008233230803","journal-title":"N Engl J Med"},{"issue":"36","key":"8759_CR82","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"issue":"11","key":"8759_CR83","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11):2317\u20132325. https:\/\/doi.org\/10.1038\/leu.2012.100","journal-title":"Leukemia"},{"issue":"9371","key":"8759_CR84","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","volume":"361","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, McConnell JP, Burritt MF, Jaffe AS (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361(9371):1787\u20131789. https:\/\/doi.org\/10.1016\/S0140-6736(03)13396-X","journal-title":"Lancet"},{"issue":"18","key":"8759_CR85","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1182\/blood-2010-05-286567","volume":"116","author":"G Palladini","year":"2010","unstructured":"Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P, Sarais G, Perlini S, Albertini R, Russo P, Foli A, Bragotti LZ, Obici L, Moratti R, Melzi d\u2019Eril GV, Merlini G (2010) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116(18):3426\u20133430. https:\/\/doi.org\/10.1182\/blood-2010-05-286567","journal-title":"Blood"},{"issue":"9","key":"8759_CR86","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989\u2013995. https:\/\/doi.org\/10.1200\/JCO.2011.38.5724","journal-title":"J Clin Oncol"},{"issue":"4","key":"8759_CR87","doi-asserted-by":"publisher","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, Caccialanza R, Perlini S, Merlini G (2014) Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica 99(4):743\u2013750. https:\/\/doi.org\/10.3324\/haematol.2013.095463","journal-title":"Haematologica"},{"issue":"7","key":"8759_CR88","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1182\/blood-2004-08-3231","volume":"105","author":"G Palladini","year":"2005","unstructured":"Palladini G, Perfetti V, Perlini S, Obici L, Lavatelli F, Caccialanza R, Invernizzi R, Comotti B, Merlini G (2005) The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105(7):2949\u20132951. https:\/\/doi.org\/10.1182\/blood-2004-08-3231","journal-title":"Blood"},{"issue":"2","key":"8759_CR89","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","volume":"109","author":"AD Wechalekar","year":"2007","unstructured":"Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 109(2):457\u2013464. https:\/\/doi.org\/10.1182\/blood-2006-07-035352","journal-title":"Blood"},{"issue":"2","key":"8759_CR90","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","volume":"109","author":"A Dispenzieri","year":"2007","unstructured":"Dispenzieri A, Lacy MQ, Zeldenrust SR, Hayman SR, Kumar SK, Geyer SM, Lust JA, Allred JB, Witzig TE, Rajkumar SV, Greipp PR, Russell SJ, Kabat B, Gertz MA (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 109(2):465\u2013470. https:\/\/doi.org\/10.1182\/blood-2006-07-032987","journal-title":"Blood"},{"issue":"10","key":"8759_CR91","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3324\/haematol.2013.084574","volume":"98","author":"S Dinner","year":"2013","unstructured":"Dinner S, Witteles W, Afghahi A, Witteles R, Arai S, Lafayette R, Schrier SL, Liedtke M (2013) Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica 98(10):1593\u20131599. https:\/\/doi.org\/10.3324\/haematol.2013.084574","journal-title":"Haematologica"},{"issue":"6","key":"8759_CR92","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28(6):1031\u20131037. https:\/\/doi.org\/10.1200\/JCO.2009.23.8220","journal-title":"J Clin Oncol"},{"issue":"5","key":"8759_CR93","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood-2017-03-771220","volume":"130","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schonland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G (2017) A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 130(5):597\u2013605. https:\/\/doi.org\/10.1182\/blood-2017-03-771220","journal-title":"Blood"},{"issue":"21","key":"8759_CR94","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1182\/blood.V124.21.4741.4741","volume":"124","author":"AD Cohen","year":"2014","unstructured":"Cohen AD, Scott EC, Liedtke M, Kaufman JL, Landau H, Vesole DH, Gomes CL, Gasparetto C, Lentzsch S, Rosenzweig M, Sanchorawala V, Smith DD, Comenzo RL, Durie BG (2014) A phase I dose-escalation study of carfilzomib in patients with previously-treated systemic light-chain (AL) amyloidosis. Blood 124(21):4741","journal-title":"Blood"},{"issue":"2","key":"8759_CR95","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","volume":"168","author":"AD Wechalekar","year":"2015","unstructured":"Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, Lachmann HJ, Hawkins PN, Pratt G, Committee B (2015) Guidelines on the management of AL amyloidosis. Br J Haematol 168(2):186\u2013206. https:\/\/doi.org\/10.1111\/bjh.13155","journal-title":"Br J Haematol"},{"issue":"4","key":"8759_CR96","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/bmt.2012.170","volume":"48","author":"MA Gertz","year":"2013","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Dingli D, Leung N, Hogan WJ, Buadi FK, Hayman SR (2013) Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant 48(4):557\u2013561. https:\/\/doi.org\/10.1038\/bmt.2012.170","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"8759_CR97","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","volume":"99","author":"RL Comenzo","year":"2002","unstructured":"Comenzo RL, Gertz MA (2002) Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99(12):4276\u20134282","journal-title":"Blood"},{"key":"8759_CR98","doi-asserted-by":"publisher","unstructured":"Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP, Myelome A, Intergroupe Francophone du Myelome I (2007) High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357 (11):1083\u20131093. doi:https:\/\/doi.org\/10.1056\/NEJMoa070484","DOI":"10.1056\/NEJMoa070484"},{"issue":"7","key":"8759_CR99","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/sj.bmt.1705106","volume":"36","author":"V Sanchorawala","year":"2005","unstructured":"Sanchorawala V, Seldin DC, Magnani B, Skinner M, Wright DG (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplant 36(7):597\u2013600. https:\/\/doi.org\/10.1038\/sj.bmt.1705106","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"8759_CR100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.7326\/0003-4819-140-2-200401200-00008","volume":"140","author":"M Skinner","year":"2004","unstructured":"Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140(2):85\u201393","journal-title":"Ann Intern Med"},{"issue":"16","key":"8759_CR101","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","volume":"118","author":"MT Cibeira","year":"2011","unstructured":"Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, Ruberg F, Meier-Ewert H, Andrea NT, Sloan JM, Finn KT, Doros G, Blade J, Skinner M (2011) Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 118(16):4346\u20134352. https:\/\/doi.org\/10.1182\/blood-2011-01-330738","journal-title":"Blood"},{"issue":"12","key":"8759_CR102","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s10067-010-1469-4","volume":"29","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Higashi S, Tomoda K, Tsukano M, Shono M (2010) Etanercept can induce resolution of renal deterioration in patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 29(12):1395\u20131401. https:\/\/doi.org\/10.1007\/s10067-010-1469-4","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8759_CR103","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/07853890.2010.548399","volume":"44","author":"T Pettersson","year":"2012","unstructured":"Pettersson T, Kantonen J, Matikainen S, Repo H (2012) Setting up TRAPS. Ann Med 44(2):109\u2013118. https:\/\/doi.org\/10.3109\/07853890.2010.548399","journal-title":"Ann Med"},{"issue":"9275","key":"8759_CR104","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(00)05252-1","volume":"358","author":"JD Gillmore","year":"2001","unstructured":"Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358(9275):24\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(00)05252-1","journal-title":"Lancet"},{"issue":"1","key":"8759_CR105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/13506120601116419","volume":"14","author":"R Kisilevsky","year":"2007","unstructured":"Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14(1):21\u201332. https:\/\/doi.org\/10.1080\/13506120601116419","journal-title":"Amyloid"},{"issue":"8853","key":"8759_CR106","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341(8853):1113\u20131116","journal-title":"Lancet"},{"issue":"5","key":"8759_CR107","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1111\/j.1600-6143.2008.02162.x","volume":"8","author":"IM Hamour","year":"2008","unstructured":"Hamour IM, Lachmann HJ, Goodman HJ, Petrou M, Burke MM, Hawkins PN, Banner NR (2008) Heart transplantation for homozygous familial transthyretin (TTR) V122I cardiac amyloidosis. Am J Transplant 8(5):1056\u20131059. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02162.x","journal-title":"Am J Transplant"},{"issue":"2","key":"8759_CR108","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1681\/ASN.2008060614","volume":"20","author":"JD Gillmore","year":"2009","unstructured":"Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH, Li LS, Wechalekar A, Hawkins PN (2009) Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 20(2):444\u2013451. https:\/\/doi.org\/10.1681\/ASN.2008060614","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"8759_CR109","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2010-01-261750","volume":"115","author":"JD Gillmore","year":"2010","unstructured":"Gillmore JD, Lachmann HJ, Wechalekar A, Hawkins PN (2010) Hereditary fibrinogen A alpha-chain amyloidosis: clinical phenotype and role of liver transplantation. Blood 115(21):4313; author reply 4314-4315. https:\/\/doi.org\/10.1182\/blood-2010-01-261750","journal-title":"Blood"},{"issue":"2\u20133","key":"8759_CR110","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","volume":"421","author":"SM Johnson","year":"2012","unstructured":"Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421(2\u20133):185\u2013203. https:\/\/doi.org\/10.1016\/j.jmb.2011.12.060","journal-title":"J Mol Biol"},{"issue":"4","key":"8759_CR111","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/13506120600960882","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MA, Kelly JW (2006) Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13(4):236\u2013249. https:\/\/doi.org\/10.1080\/13506120600960882","journal-title":"Amyloid"},{"issue":"10","key":"8759_CR112","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","volume":"34","author":"MA Gertz","year":"2016","unstructured":"Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schonland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M (2016) First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 34(10):1097\u20131103. https:\/\/doi.org\/10.1200\/JCO.2015.63.6530","journal-title":"J Clin Oncol"},{"issue":"10 Pt 2","key":"8759_CR113","first-page":"3831S","volume":"9","author":"A Solomon","year":"2003","unstructured":"Solomon A, Weiss DT, Wall JS (2003) Therapeutic potential of chimeric amyloid-reactive monoclonal antibody 11-1F4. Clin Cancer Res 9(10 Pt 2):3831S\u20133838S","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8759_CR114","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0002-9440(10)64639-1","volume":"157","author":"R Hrncic","year":"2000","unstructured":"Hrncic R, Wall J, Wolfenbarger DA, Murphy CL, Schell M, Weiss DT, Solomon A (2000) Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 157(4):1239\u20131246. https:\/\/doi.org\/10.1016\/S0002-9440(10)64639-1","journal-title":"Am J Pathol"},{"issue":"13","key":"8759_CR115","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1182\/blood-2010-03-273797","volume":"116","author":"JS Wall","year":"2010","unstructured":"Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, Wells KJ, Fu Y, Stabin MG, Weiss DT, Solomon A (2010) Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood 116(13):2241\u20132244. https:\/\/doi.org\/10.1182\/blood-2010-03-273797","journal-title":"Blood"},{"issue":"sup1","key":"8759_CR116","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","volume":"24","author":"CV Edwards","year":"2017","unstructured":"Edwards CV, Gould J, Langer AL, Mapara M, Radhakrishnan J, Maurer MS, Raza S, Mears JG, Wall J, Solomon A, Lentzsch S (2017) Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid 24(sup1):58\u201359. https:\/\/doi.org\/10.1080\/13506129.2017.1292900","journal-title":"Amyloid"},{"issue":"12","key":"8759_CR117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052686","volume":"7","author":"JS Wall","year":"2012","unstructured":"Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, Macy S, Donnell R, Barbour R, Seubert P, Schenk D (2012) AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 7(12):e52686. https:\/\/doi.org\/10.1371\/journal.pone.0052686","journal-title":"PLoS One"},{"issue":"3","key":"8759_CR118","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1080\/13506129.2016.1205974","volume":"23","author":"M Renz","year":"2016","unstructured":"Renz M, Torres R, Dolan PJ, Tam SJ, Tapia JR, Li L, Salmans JR, Barbour RM, Shughrue PJ, Nijjar T, Schenk D, Kinney GG, Zago W (2016) 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis (dagger). Amyloid 23(3):168\u2013177. https:\/\/doi.org\/10.1080\/13506129.2016.1205974","journal-title":"Amyloid"},{"issue":"12","key":"8759_CR119","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","volume":"373","author":"DB Richards","year":"2015","unstructured":"Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373(12):1106\u20131114. https:\/\/doi.org\/10.1056\/NEJMoa1504942","journal-title":"N Engl J Med"},{"issue":"7320","key":"8759_CR120","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature09494","volume":"468","author":"K Bodin","year":"2010","unstructured":"Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ, Minogue S, Dhillon AP, Taylor GW, Bradwell AR, Petrie A, Gillmore JD, Bellotti V, Botto M, Hawkins PN, Pepys MB (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468(7320):93\u201397. https:\/\/doi.org\/10.1038\/nature09494","journal-title":"Nature"},{"issue":"6886","key":"8759_CR121","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/417254a","volume":"417","author":"MB Pepys","year":"2002","unstructured":"Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN (2002) Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417(6886):254\u2013259. https:\/\/doi.org\/10.1038\/417254a","journal-title":"Nature"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-019-08759-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-019-08759-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T14:08:16Z","timestamp":1606399696000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-019-08759-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["8759"],"URL":"https:\/\/doi.org\/10.1007\/s12016-019-08759-4","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"2 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}